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The hepatic glucose fasting response is gaining traction as a therapeutic pathway to enhance
hepatic and whole-host metabolism. However, the mechanisms underlying these metabolic effects
remain unclear. Here, we demonstrate the epidermal-type lipoxygenase, eLOX3 (encoded by its
gene, Aloxe3), is a potentially novel effector of the therapeutic fasting response. We show that
Aloxe3 is activated during fasting, glucose withdrawal, or trehalose/trehalose analogue treatment.
Hepatocyte-specific Aloxe3 expression reduced weight gain and hepatic steatosis in diet-induced
and genetically obese (db/db) mouse models. Aloxe3 expression, moreover, enhanced basal
thermogenesis and abrogated insulin resistance in db/db diabetic mice. Targeted metabolomics
demonstrated accumulation of the PPARγ ligand 12-KETE in hepatocytes overexpressing Aloxe3.
Strikingly, PPARγ inhibition reversed hepatic Aloxe3–mediated insulin sensitization, suppression of
hepatocellular ATP production and oxygen consumption, and gene induction of PPARγ coactivator1α (PGC1α) expression. Moreover, hepatocyte-specific PPARγ deletion reversed the therapeutic
effect of hepatic Aloxe3 expression on diet-induced insulin intolerance. Aloxe3 is, therefore,
a potentially novel effector of the hepatocellular fasting response that leverages both PPARγmediated and pleiotropic effects to augment hepatic and whole-host metabolism, and it is, thus, a
promising target to ameliorate metabolic disease.
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Leveraging the generalized fasting and caloric restriction responses to mitigate metabolic disease is under
intense investigation as a novel therapeutic approach against obesity, diabetes mellitus, and nonalcoholic
fatty liver disease (NAFLD) (1, 2). The hepatocyte is uniquely positioned at the nexus of the portal circulation — where dietary macronutrients are sensed and triaged to their metabolic fate — and the peripheral
circulation, from which macronutrients are taken up and utilized or stored. Its unique anatomic positioning
also defines the hepatocyte’s role in coordinating the transition from fed to fasting states. Specifically, the
hepatocyte senses fat, protein, and carbohydrate content and rapidly alters its metabolism and its endocrine
functions to coordinate peripheral responses. However, the therapeutic promise of caloric restriction and
generalized macronutrient fasting remains limited by its clinical impracticality and unsustainability. Our
laboratory and others (1, 9, 11) have therefore examined specific pathways through which fasting and
fasting-like mechanisms can be molecularly or pharmacologically leveraged to the benefit of the host.
Upon physiological macronutrient withdrawal, the canonical hepatic response is to shift to mobilize
glycogen and oxidize fat from stores to produce glucose and ketone body fuel for the brain and heart. This
begins with activation of proximal macronutrient sensing kinases, AMPK, and mTOR. These kinases act
as primary regulators of macroautophagy as well as transcriptional fasting programming by hepatic transcription factors, including transcription factor EB (3); PPARγ coactivator-1α (PGC1α) (4); and transcriptional modifiers such as the sirtuin family of protein deacetylases (5). FGF21 is released from the liver of
fasting rodents and humans to promote adipose “browning” (mitochondrial uncoupling to promote heat
generation; ref. 6). The net effect of this signaling initiation is a networked cascade through which the liver
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provides energy substrate to the periphery during fasting and promotes peripheral insulin sensitivity for
efficient absorption of the next meal.
We recently demonstrated that blocking hepatic glucose transporters genetically or pharmacologically
closely recapitulates the therapeutic metabolic effects of generalized macronutrient fasting (7–11). Pharmacologic glucose transport blockade using the disaccharide glucose transporter inhibitor trehalose blocked
mTOR and activated AMPK-dependent autophagic flux (9, 12). Moreover, trehalose blocked diet- and
genetically induced steatosis via ATG16L1- and AMPK-dependent mechanisms, and it enhanced peripheral thermogenesis via hepatocyte TFEB- and FGF21-dependent mechanisms (11). Consistent with data
from pharmacological glucose transporter (GLUT) blockade, genetic deletion of the hepatocyte GLUT8
similarly increased basal and fasting heat generation (10), enhanced hepatocyte fat oxidation, and inhibited
hepatic de novo lipogenesis and triacylglycerol generation in mice fed a high-fructose diet (7, 8). Notably,
in those experiments, GLUT8 blockade was associated with enhanced insulin tolerance, enhanced hepatic
PPARγ expression, and concomitant activation of the PPARγ target UCP2 (8). Conversely, GLUT8 was
upregulated in the livers of genetically diabetic mice (13). Together, prior data suggest that pharmacologic
and genetic activation of hepatic glucose fasting–like responses are sufficient to mitigate metabolic disease.
However, the mechanisms underlying this protection remain enigmatic.
Recent data illuminate a role for cellular lipoxygenases in the pathogenesis and protection from metabolic disease. In humans, a recent large cohort of adults with type 2 diabetes demonstrated a potentially
protective role for 5-lipoxygenases ALOX5 and ALOX5AP against diabetes mellitus (14). Conversely,
ALOX12/15 inhibition in rodent models inhibited oxidative stress, β cell deterioration, hepatic steatosis, and systemic inflammation (15–18). Together, these data suggest that intracellular lipid intermediary
metabolism drives both tissue-level and whole-organism metabolic homeostasis. The concept that the fasting state might modulate lipoxygenase activity as part of the broadly adaptive effects of fasting on metabolism remained heretofore unexplored.
Here, we identified eLOXE3 (encoded by the Aloxe3 gene) as a fasting-induced epidermal-type lipoxygenase that acts as a potentially novel effector of the hepatic glucose fasting response in vitro and in vivo.
Targeted Aloxe3 overexpression induced robust generation of the PPARγ ligand (19, 20) 12-KETE. In vivo,
hepatic Aloxe3 expression enhanced insulin sensitivity, attenuated weight gain, and reduced hepatic steatosis in both diet- and genetically induced steatosis models. Moreover, hepatic Aloxe3 expression mitigated
diet-induced dyslipidemia, and db/db mice expressing Aloxe3 exhibited attenuated weight gain, enhanced
basal caloric expenditure, and PPARγ-dependent insulin sensitivity. Strikingly, we demonstrate that hepatocyte-specific PPARγ deletion is absolutely required for the insulin-sensitizing effect of hepatic Aloxe3
induction. Taken together, Aloxe3 is a fasting-responsive hepatocyte effector that is sufficient to attenuate
insulin resistance, weight gain, and hepatic fat deposition in dietary and genetically obese models, in part
by activating hepatic PPARγ. Aloxe3 is, thus, a novel therapeutic mechanism downstream of the fasting
response, which can be leveraged against metabolic disease.

Results
To test the hypothesis that Aloxe3 is induced by acute fasting or pseudo-fasting conditions, we subjected WT mice to 48-hour fasting. During acute fasting, hepatic Aloxe3 expression was increased and
sustained at least through 48 hours (Figure 1A). Oral administration of the fasting-mimetic hepatic
glucose transport inhibitor trehalose (3% PO, ad libitum), similarly induced Aloxe3 expression after
24-hour and 48-hour trehalose feeding (Figure 1B). The hepatic Aloxe3 response to fasting contrasted
with fasting Aloxe3 expression in white adipose tissue (WAT), wherein Aloxe3 mediates fat differentiation and lipid storage. Accordingly, Aloxe3 was significantly suppressed during both fasting and trehalose feeding in epididymal WAT (Figure 1, A and B, respectively). We then modeled Aloxe3 expression
in vitro to determine whether fasting-induced Aloxe3 expression is cell-autonomously regulated. Isolated primary murine hepatocytes were subjected to treatment by either low serum and glucose (0.5%
serum, 1 g/l glucose) or trehalose (Figure 1C). In addition, we characterized fasting-mimetic effects
of a trehalose analogue that resists enzymatic degradation by trehalases (21–23), called lactotrehalose (α-D-glucopyronosyl-(1,1)-α-D-galactopyranoside; Figure 1C and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.120794DS1). In
each case, Aloxe3 expression was significantly increased, most potently by trehalose and lactotrehalose
(Figure 1C and Supplemental Figure 1).
insight.jci.org   https://doi.org/10.1172/jci.insight.120794
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Figure 1. Aloxe3 is induced in response to fasting and pseudofasting. (A) Aloxe3 expression in liver and white adipose tissue (WAT) from fasting WT mice
(0–48 hours [h]). n = 6 each of fed, 12 h fasting, and 24 h fasting mice. For 48 h fasting mice, n = 7. (B) Aloxe3 expression in WT mice fed oral trehalose (3%
in sterile water fed ad libitum, 0–48 h). For control and trehalose (24 h) mice, n = 5 and 6. For 48 h trehalose-treated mice, n = 6. (C) Aloxe3 expression in
isolated primary murine hepatocytes treated with 0.5% FCS/1 g/l glucose media, 100 mM trehalose, or 100 mM lactotrehalose (24 h). n = 4 per group. (D)
Aloxe3 expression in trehalose-treated isolated primary hepatocytes pretreated with or without 5 mM pyruvate. n = 4 per group. (E) Aloxe3 expression in
trehalose-treated WT and Atg16l1-mutant mice in vivo (24 h). n = 6 per group. (F) Aloxe3 expression in response to trehalose in the presence or absence of
kinase-dead AMPK overexpression or siRNA-mediated AMPK knockdown. n = 4 per group. (G) Aloxe3 expression in response to trehalose in the presence or
absence of antisense oligonucleotide (ASO) directed against PGC1, or FGF21. FGF receptor 1–4 inhibitor (LY2874455) was included as a control to demonstrate
Aloxe3 blockade in context. n = 4 per group. (H) Fasting-responsive marker gene expression in the presence or absence of trehalose following treatment with
or without Aloxe3-directed siRNA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 2-tailed t test with Bonferroni-Dunn post hoc correction versus
untreated controls group or versus the bracketed comparison group where indicated.

In light of evidence that Aloxe3 is a potentially novel hepatocyte fasting-responsive factor in mice
and in isolated murine hepatocytes, we evaluated whether this factor is expressed in isolated human
hepatocytes and in Huh7 and HepG2 human hepatoma cell lines. Consistent with immunoblot and
immunohistochemical eLOX3 protein detection in human liver tissue (24), quantitative PCR (qPCR)
analysis demonstrated ALOXE3 expression in both HepG2 and in primary human hepatocytes (Supplemental Figure 2).
insight.jci.org   https://doi.org/10.1172/jci.insight.120794
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Figure 2. Aloxe3 and trehalose induce the PPARγ ligand 12-KETE in murine hepatocytes. (A) Arachidonic acid metabolism mediated by lipoxygenases
12-LOX, 5-LOX, and eLOX3 (adapted from refs. 26, 29, 58, 59). (B) Lipoxygenase activity in primary murine hepatocytes upon overexpression of β galactosidase or Aloxe3. n = 3 from 1 representative experiment of 2 experiments with similar results. (C and D) Quantitative GC-MS analysis of the stable lipoxygenase reaction products 12-KETE, 5-HETE, and 12-HETE. Data represent 4 independent cultures per group from 1 experiment, representing 2 independent
experiments with similar results. **P < 0.01 and ***P < 0.001 by 2-tailed t test with Bonferroni-Dunn post hoc correction versus untreated controls group
or versus the bracketed comparison group where indicated.

To determine whether Aloxe3 induction depended upon energy substrate deficit, we treated primary hepatocytes with trehalose in the presence or absence of pyruvate. This provided energy substrate for the cell, independently of glucose transporter blockade. Pyruvate reversed trehalose-induced Aloxe3 induction by ~60% (P
< 0.0001), suggesting that Aloxe3 expression is at least partly energy substrate dependent (Figure 1D). In light
of our prior data in which we demonstrated that the autophagy complex protein ATG16L1 was required for
autophagic and antisteatotic effects of trehalose in hepatocytes (9, 25), we examined whether ATG16L1 is
required for Aloxe3 induction. We treated primary hepatocytes from WT littermates or from mice with homozygous hypomorphic Atg16l1 alleles (Atg16l1HM) with or without trehalose (24 hours). Aloxe3 mRNA quantification revealed robust Aloxe3 induction in WT hepatocytes, which was not suppressed in Atg16l1HM hepatocytes (Figure 1E). Similarly, AMPK inhibition (by kinase-dead AMPK overexpression or by Aloxe3 siRNA
transfection; Figure 1F) and PPARα, PGC1α, and FGF21 knockdown each failed to reverse Aloxe3 induction
insight.jci.org   https://doi.org/10.1172/jci.insight.120794

4

RESEARCH ARTICLE

after trehalose treatment or glucose and serum withdrawal (Figures 1G and 1H). Accordingly, moderate hepatocyte-specific overexpression of the fasting-induced transcription factor SIRT1 did not induce Aloxe3 expression (Supplemental Figure 3). In contrast, siRNA-based Aloxe3 knockdown attenuated PPARα and PGC1α at
baseline and during glucose and serum withdrawal from hepatocytes in vitro, without effects on FGF21 expression (Figure 1H). Together, our data demonstrate that Aloxe3 is a hepatocyte lipoxygenase that is induced by
glucose transporter blockade and energetic deficit via a mechanism that does not require canonical ATG16L1dependent and AMPK-PGC1α/PPARα-FGF21 fasting mechanisms.
eLOX3 generates the PPARγ ligand 12-KETE and an epoxyalcohol from 12-HpETE in the metabolism
of plasma membrane arachidonic acid (Figure 2A) (26–30). We tested whether Aloxe3 mediates similar lipid
metabolism in hepatocytes upon forced Aloxe3 expression. We first evaluated the effect of Aloxe3 overexpression on hepatocyte lipoxygenase activity by measuring LOX substrate oxidation in cell extracts from hepatocytes overexpressing β galactosidase (β-gal) or Aloxe3. Consistent with prior data demonstrating intrinsic,
latent dioxygenase activity of eLOX3 (31), Aloxe3 overexpression significantly increased total oxidized LOX
substrate accumulation (Figure 2B) and 12-KETE accumulation in primary hepatocytes (Figure 2C). This
effect of Aloxe3 overexpression on 12-KETE accumulation was indeed phenocopied by trehalose treatment
(Figure 2C). Moreover, Aloxe3 overexpression decreased the abundance of alternate arachidonic acid metabolic pathway products 5-HETE and 12-HETE (Figure 2D).
To ascertain transcriptome-wide effects of forced Aloxe3 overexpression, we next treated primary hepatocytes with adenovirus encoding β-gal or Aloxe3 prior to RNA sequencing (RNA-seq) analysis. Pathway
analysis revealed that 5 of the 10 most downregulated processes in Aloxe3-overexpressing cells were devoted
to inflammatory signaling, including TNFα, NF-κB, chemokine signaling, cytokine receptor signaling, and
MAPK signaling (Figure 3A). Given these findings, and in light of the fact that Aloxe3 upregulation by
trehalose correlates with reduced diet- and genetically induced steatosis (9, 25), we examined whether
Aloxe3 attenuates fat-induced inflammatory signaling and triglyceride (TG) accumulation. Primary hepatocytes treated with BSA-conjugated fatty acids (FA) induced Il1b and Tnfa gene expression, as well as TG
accumulation (Figure 3, B and C). These FA-induced effects on TG accumulation and Il1b and Tnfa gene
expression effects were reversed in FA-treated cultures overexpressing Aloxe3.
Aloxe3-deficient mice are not amenable to in vivo metabolic studies because germline Aloxe3 deficiency
results in postnatal mortality secondary to massive skin permeability and water loss (32). To evaluate the
in vivo metabolic consequences of hepatocyte Aloxe3 activation, we tested the in vivo effects of hepatocytedirected Aloxe3 expression. We first confirmed overexpression of the Aloxe3 transgene in liver (Figure 4A)
without changes in Aloxe3 expression in skeletal muscle, WAT, or brown adipose tissue (not shown). This
correlated with upregulation of fasting and oxidative genes in unperturbed Aloxe3-overexpressing mice,
including Aloxe3 (Figure 4A), Ppargc1a (PGC1), hepatocyte nuclear factor 4α (Hnf4A/HNF4α), and phosphoenolpyruvate carboxykinase 1 (Pck1, Figure 4A.).
We next evaluated the effect of hepatic Aloxe3 expression in mice fed low-fat diet (LFD) or steatogenic,
high trans-fat/cholesterol diet (HTFC) (12 weeks). Mice overexpressing Aloxe3 fed HTFC gained significantly less weight, had lower total body mass (Figure 4B), and had lower body fat mass (Figure 4C) without
changes in lean mass (not shown) when compared with Gfp-overexpressing mice fed HTFC. Accordingly,
low density lipoprotein-cholesterol (LDL-C) and total cholesterol were significantly lowered in HTFC-fed
mice overexpressing Aloxe3 (Figure 4D). Indices of glucose homeostasis were also improved by Aloxe3
overexpression in HTFC-fed mice (Figure 4, E–G). Specifically, HTFC feeding increased circulating insulin
and homeostatic model assessment– insulin resistance (HOMA-IR) in GFP-overexpressing mice (Figure
4, E and G), without altering fasting plasma glucose (Figure 4F). In contrast, HTFC-fed mice overexpressing hepatic Aloxe3 were protected from HTFC-induced hyperinsulinemia and insulin resistance (Figure
4, E and G). Indeed, fasting glucose was also lowered in Aloxe3-overexpressing, HTFC-fed mice when
compared with GFP-expressing, HTFC-fed mice (Figure 4F). Together, hepatocyte Aloxe3 expression was
sufficient to reduce diet-induced weight gain, body fat accumulation, dyslipidemia, and insulin resistance.
We next examined hepatic lipid metabolism in GFP- and Aloxe3-overexpressing mice fed LFD or HTFC.
Frozen liver sections from HTFC-fed mice exhibited increased Oil Red O staining and macrosteatosis when
compared with LFD-fed mice. Consistent with prior models of PPARγ activation (33–35), Aloxe3 expression
in LFD-fed mice resulted in a mild basal TG accumulation (Figure 5, A and B). However, we did not observe
evidence of hepatic inflammation or fibrosis by histological analysis of H&E- or trichrome-stained liver
sections in LFD-fed mice after 12 weeks Aloxe3 overexpression (Supplemental Figure 4). Also consistent
insight.jci.org   https://doi.org/10.1172/jci.insight.120794
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Figure 3. Aloxe3 reduces inflammatory signaling and steatosis in hepatocytes. (A) RNA-seq analysis of the top 9 downregulated genes in primary hepatocytes expressing either β galactosidase or Aloxe3. n = 3 from a single RNA-seq run performed once. The P value for significantly downregulated pathways
is demonstrated as (–Log[P value]). (B) Hepatic TG accumulation and (C) IL-1β or TNFα expression in hepatocytes treated with BSA-conjugated fatty acids
with or without Aloxe3 expression. n = 4 in B and n = 4 in C, single representative experiments, which were repeated twice with similar results. ***P <
0.001 and ****P < 0.0001 by 2-tailed t testing with Bonferroni-Dunn post hoc correction versus the bracketed comparison group as indicated.

with prior reports on hepatic PPARγ activation, Aloxe3 overexpression modestly but significantly protected
from HTFC-induced TG accumulation that took on a microsteatotic staining pattern (Figure 5, A and B).
No changes in hepatic LDL-C or total cholesterol were observed (Figure 5, C and D) upon hepatic Aloxe3
overexpression in LFD- or HTFC-fed mice. None of our genetic or dietary manipulations had any effect on
hepatic synthetic function, as ascertained by quantitative circulating albumin levels (Figure 5E).
To examine mechanistically how Aloxe3 might activate hepatocyte-starvation–like responses, we evaluated the effects of Aloxe3 overexpression on mitochondrial respiratory function at the cellular and molecular
levels. RNA-seq analysis of primary hepatocytes overexpressing Aloxe3 revealed that 6 of the 10 most downregulated molecular processes encompassed mitochondrial electron transport function, including proton
transport, ATPase activity, transmembrane ion transport, and hydrogen export (Figure 6A). We therefore
tested functionally the hypothesis that Aloxe3 mitigates ATP production by inducing hepatocyte mitochondrial uncoupling. Seahorse analysis of hepatocytes overexpressing Aloxe3 exhibited elevated proton leak,
ATP production, and coupling efficiency, concomitant with suppressed basal oxygen consumption rate
and enhanced glycolytic rate when compared with hepatocytes expressing β-gal (Figure 6B). Each of these
parameters was partly or fully reversed in the presence of the PPARγ inhibitor GW9662 (Figure 6B). No
changes in nonmitochondrial oxygen consumption were observed (Figure 6C), suggesting that Aloxe3 specifically affected mitochondrial energy metabolism.
Mechanistic interrogation in vivo was executed to determine whether hepatocyte Aloxe3 mediated peripheral insulin and glucose homeostasis in a leptin-dependent manner. To that end, we overexpressed Aloxe3
or GFP in db/db mice, which lack the leptin receptor. Again, in the liver, we observed modest, statistically
insight.jci.org   https://doi.org/10.1172/jci.insight.120794
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Figure 4. Enhanced whole-body metabolism in mice ALOXE3-overexpressing mice. (A) qPCR quantification of expression for oxidative and fastingresponse genes in unperturbed mice expressing hepatocyte GFP or Aloxe3. (B) Body weight over time in low-fat or high–trans fat/cholesterol diet–
fed mice expressing hepatocyte GFP or Aloxe3. (C) Body fat content in mice fed HTFC or LFD with or without hepatic Aloxe3 overexpression. (D)
LDL-C and total cholesterol in mice fed HTFC or LFD with or without hepatic Aloxe3 overexpression. (E–G) Circulating insulin, glucose, and calculated HOMA-IR in LFD- and HTFC-fed mice overexpressing hepatocyte GFP or Aloxe3. Number of mice in each group is: 5, AAV8GFP LFD; 10, AAV8GFP
HTFC; 5, AAV8ALOXE3 LFD; and 10, AAV8ALOXE3 HTFC. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 2-tailed t test with Bonferroni-Dunn
post hoc correction versus the bracketed comparison group as indicated.
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Figure 5. Reduced hepatic steatosis correlates with Aloxe3-induced fasting responses. (A) Oil Red O staining in livers from low-fat or high–trans fat/
cholesterol–fed mice overexpressing GFP or Aloxe3. (B–D) Hepatic tissue quantification of triglycerides, LDL-C, total cholesterol in low-fat or high–trans
fat/cholesterol–fed mice overexpressing empty vector or Aloxe3. (E) Serum albumin measurements in mice analyzed in A–D Number of mice in each group
is: 5, AAV8GFP LFD; 10, AAV8GFP HTFC; 5, AAV8ALOXE3 LFD; and 10, AAV8ALOXE3 HTFC. Scale bar: 100 μm. **P < 0.01 and ****P < 0.0001 by 2-tailed t test with
Bonferroni-Dunn post hoc correction versus untreated controls group or versus the bracketed comparison group where indicated.

significant attenuation of hepatic TG accumulation in db/db mice overexpressing Aloxe3 when compared
with db/db controls (Figure 7, A and B). We confirmed Aloxe3 overexpression correlated with increases in
oxidative and fasting-response genes Ppargc1a, Hnf4a, and Pc1 (Figure 7C). Moreover, Aloxe3 overexpression
reduced genetic markers of de novo lipogenesis in db/db mice, including Fsp27, Scd1, and Fasn (Figure 7D).
Concomitant PPARγ inhibition by the inhibitor GW9662 produced either statistically significant or trends
toward significant reversal in each of these Aloxe3-altered marker genes (Figure 7, C and D).
Although baseline weights were not statistically different, db/db mice overexpressing Aloxe3 gained
significantly less weight and had a lower end-of-trial weight than db/db mice over the 28-day trial (Figure
8A). Indirect calorimetry revealed that the attenuated weight gain in aloxe3 db/db mice was associated
with enhanced light- and dark-cycle heat generation and O2-CO2 exchange (Figure 8, B-D). Neither heat
generation nor O2-CO2 exchange in Aloxe3db/db was affected by GW9662 coadministration (Figure 8, B–D).
Because hepatic Aloxe3 expression enhanced peripheral insulin sensitivity in HTFC-fed mice
(Figure4), and because PPARγ agonism by thiazolidinediones (TZDs) enhances peripheral insulin
sensitivity (36, 37), we evaluated whether Aloxe3 enhances peripheral insulin and glucose homeostasis dependent on PPARγ and yet independent of the leptin receptor. Fasting circulating insulin and
HOMA-IR were significantly lower in Aloxe3db/db mice without changes in circulating glucose when
compared with db/db mice expressing GFP. The reduction in circulating insulin and HOMA-IR were
reversed in mice concomitantly treated with the PPARγ inhibitor GW9662, suggesting that Aloxe3
improves glucose and insulin homeostasis via a PPARγ-dependent mechanism. In contrast with our
diet-induced model, however, targeted hepatic Aloxe3 expression did not reduce circulating lipids in
a leptin receptor–deficient mice. Together, the data in our leptin-deficient model elucidate leptin- and
PPARγ-dependent functions by Aloxe3.
insight.jci.org   https://doi.org/10.1172/jci.insight.120794
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Figure 6. Hepatic PPARγ is required for Aloxe3 to induce hepatic energetic inefficiency. (A) RNA-seq analysis of the top 5 downregulated molecular
processes in hepatocytes overexpressing Aloxe3. Highlighted are ATPase-related and mitochondrial coupling processes. Graphed is logFC relative to
cultures expressing β galactosidase. n = 3 from a single RNA sequencing run performed once. (B and C) Seahorse XF96 analysis of proton leak, basal
OCR, ATP production, coupling efficiency, and nonmitochondrial oxygen consumption in AML12 cells overexpressing Aloxe3 with or without GW9662
(PPARγ inhibitor) treatment. n = 8 independent cultures combined from 2 distinct experimental runs. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P <
0.0001 by 2-tailed t testing with Bonferroni-Dunn post hoc correction versus the bracketed comparison group as indicated.

To gain further specificity regarding the role of hepatocyte PPARγ in Aloxe3-enhanced insulin sensitivity, we
generated mice harboring a hepatocyte-specific PPARG deletion (hereafter referred to as PPARγ-LKO mice) by
crossing mice with homozygous floxed Pparg alleles with mice expressing Cre recombinase driven by the albumin promoter. Mice were placed on a chow or Western diet (WD) to induce insulin resistance over 12 weeks;
they were then subjected to insulin tolerance testing (ITT, Figure 9, A and B). Area under the ITT curve analysis
revealed that WD feeding increased AUC in GFP-overexpressing animals, whereas AUC was reduced in Aloxe3overexpressing animals. In striking contrast, WD-fed Aloxe3-overexpressing PPARγ-LKO mice had a significantly elevated AUC when compared with WD-fed Aloxe3-overexpressing mice harboring WT hepatic PPARγ.
insight.jci.org   https://doi.org/10.1172/jci.insight.120794
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Figure 7. Reduced hepatic steatosis correlates with Aloxe3-induced fasting and reduction of de novo lipogenesis. (A) H&E staining in livers from
low-fat or high–trans fat/cholesterol–fed mice overexpressing empty vector or Aloxe3. (B) Hepatic tissue triglyceride quantification in db/db mice
overexpressing GFP or Aloxe3 in the presence or absence of GW9662. (C and D) qPCR quantification of expression for oxidative and fasting-response
genes (C) and de novo lipogenic genes (D) in db/db mice expressing GFP or Aloxe3 with or without GW9662 administration. Number of mice in each
group is: 10, db/db AAV8GFP; 10, db/db AAV8ALOXE3; 10, AAV8ALOXE3 + GW9662. Scale bar: 100 μm. **P < 0.01, or ****P < 0.0001 by 2-tailed t testing with
Bonferroni-Dunn post hoc correction versus the bracketed comparison group as indicated.

Discussion
The concept of the fasting and caloric restriction response as a therapeutic to be leveraged in longevity, healthspan, and metabolism from rodents to early primates to humans (1, 38–43) is gaining traction.
Already in the clinical realm, caloric restriction improved multiple indices related to aging, cardiovascular
disease, and diabetes mellitus (2, 44–46). However, strict and prolonged adherence to caloric restriction,
intermittent fasting, or any intensive dietary restriction directed toward weight loss carries with it several practical barriers. Therefore, identifying the therapeutic determinants of the hepatic glucose fasting
response opens the promise of novel, targeted, and sustainable treatments against metabolic and other diseases. Here, we show that Aloxe3 is activated by the adaptive hepatic fasting response and is itself sufficient
to enhance insulin sensitivity, increase basal caloric expenditure, and reduce diet-induced weight gain and
fat accumulation, hepatic steatosis, and dyslipidemia.
insight.jci.org   https://doi.org/10.1172/jci.insight.120794
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Figure 8. Enhanced whole-body energy metabolism in db/db diabetic mice overexpressing Aloxe3. (A) Body weight over time in db/db mice
expressing empty vector or Aloxe3 in the presence or absence of GW9662. (B) Heat generation over time in db/db mice expressing GFP or Aloxe3. (C
and D) Indirect calorimetric quantification of light- and dark-cycle heat generation in db/db mice expressing Aloxe3 or GFP treated with or without
GW9662. (E) Fasting serum insulin determined by ELISA, serum glucose determined by colorimetric assay, and calculated HOMA-IR index based on
glucose and insulin data. (F–I) Serum TG, cholesterol, LDL-C, and FFA content in db/db mice with or without hepatic Aloxe3 overexpression and with
or without GW9662 treatment. Number of mice in each group is: 10, db/db AAV8GFP; 10, db/db AAV8ALOXE3; 10, AAV8ALOXE3 + GW9662. *P < 0.05, **P <
0.01, ***P < 0.001, and < 0.0001 by 2-tailed t test with Bonferroni-Dunn post hoc correction versus bracketed comparison groups.
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Figure 9. Insulin sensitization by Aloxe3 requires hepatic PPARγ. (A) Insulin tolerance testing in WT or PPARγ-LKO mice expressing hepatic GFP
or Aloxe3 after chow or Western diet. (B) Quantification of total area under the glucose time curve. **P < 0.01 and ***P < 0.001 by 2-tailed t test
with Bonferroni-Dunn post hoc correction between bracketed comparison groups as indicated. Number of mice in each group is: 4, AAV8GFP Chow; 5,
AAV8GFP WD; 5, AAV8ALOXE3 WD; and 4, PPARγ-LKO AAV8ALOXE3 WD.

Fully defining the metabolic functions of Aloxe3 has been previously limited by its basal tissue
expression and distribution and by the dramatic phenotype observed in animals and humans deficient
for this enzyme. Aloxe3 was first identified as an epidermal-type lipoxygenase that mediates skin differentiation via hydroperoxide isomerase activity (27, 47). Humans born with a defect in this gene
develop ichthyosiform disease, characterized by profound skin barrier dysfunction and transepidermal
water loss (28, 30). This was confirmed in murine models of Aloxe3 deficiency, which succumb to massive dehydration without intervention shortly after birth (32). Subsequent work demonstrated a role
for Aloxe3 in adipocyte differentiation via PPARγ agonism in cultured adipocytes, as well (29). This
introduced the possibility that Aloxe3 has important functions that extend beyond epidermal tissues.
However, a potential function in liver was largely ignored, perhaps in part because nonfasting mRNA
is relatively low when compared with epidermis and tongue by Northern blot detection (32) and by
reverse transcription PCR analysis of murine liver (48). However, we show here that serum and glucose
withdrawal, trehalose and lactotrehalose (trehalose analog) treatment in vitro, trehalose feeding, and
acute fasting in vivo each robustly induce Aloxe3 mRNA expression. This raised the prospect that Aloxe3
mediates part of the physiological hepatic fasting response. We postulate that the observed increased
insulin sensitivity in hepatic Aloxe3–overexpressing mice reflects an adaptive response that enhances
peripheral insulin sensitivity in preparation for a subsequent meal after prolonged fasting. This function
would be particularly useful to maximize macronutrient absorption for animals in which meals are few
and far between (e.g., intermittently fasting or hibernating animals). Indeed, this teleological rationale
has been proposed for other physiological fasting-induced pathways, such as FGF21 signaling (49, 50).
The data herein demonstrate that Aloxe3 ameliorated the diet-induced obesity and db/db diabetic phenotypes, at least in part, via a PPARγ-dependent mechanism — most prominently with regard to the insulin-sensitizing effects of Aloxe3. Aloxe3 overexpression and trehalose treatment in hepatocytes induced the
PPARγ ligand 12-KETE at cellular concentrations that appear to be physiologically relevant (19). Indeed,
12-KETE induced sebocyte PPARγ signaling at ~1,500 ng/ml (19), whereas our calculated 12-KETE concentrations in Aloxe3-overexpressing hepatocytes (accounting for a hepatocyte volume of roughly 3 fL, femtoliters; ref. 51) indicate concentration of 12-KETE is in the range of 1,000 ng/ml (Figure 2C). In addition,
PPARγ blockade by GW9662 administration in isolated hepatocytes and in vivo reversed Aloxe3-mediated
changes in hepatocyte oxygen consumption rate, insulin resistance, and PGC1α upregulation. Finally, liver-specific PPARγ deletion abrogated Aloxe3-enhanced insulin sensitivity. Together, these data introduce
a potentially novel hepatic Aloxe3–PPARγ axis that improves whole-body insulin sensitivity. These findings are consistent with the previously demonstrated control of peripheral insulin sensitivity via hepatic
PPARγ in ob/ob mice (34, 35). However, given that GW9662 did not significantly reverse Aloxe3 effects on
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hepatic fat accumulation and whole-body thermogenesis, our data indicate that Aloxe3 exerts both PPARγdependent and -independent functions to enhance hepatic and extrahepatic metabolic homeostasis.
It should be noted that genetic disruption of both 12-LOX and 15-LOX in multiple diabetic models
largely recapitulates the Aloxe3-mediated enhancement of hepatic insulin sensitivity and reduced hepatic
steatosis (15–17). Therefore, it is plausible that — in addition to (or perhaps in lieu of) generating the
PPARγ ligand 12-KETE — eLOX3 either depletes 12-LOX products 12-HpETE and 12-HETE (Figure 2)
to the host’s benefit, or 12-LOX and 15-LOX deletion shunts arachidonic acid down the eLOX3 enzymatic
pathway to activate PPARγ. A third distinct possibility is that Aloxe3 mediates its PPARγ-activating effects
independently of upstream lipoxygenases. Three key pieces of data support this possibility. First, hepatocytes are not considered overall to be a significant source of total lipoxygenase activity. This is confirmed
by our own data suggesting that basal intrinsic hepatocyte lipoxygenase activity is relatively low — on the
order of 1–10 fmol/mg/min (Figure 2B). Second, eLOX3 exhibits latent intrinsic dioxygenase activity,
although this catalysis is relatively inefficient when compared with its hydroperoxide isomerase activity
(31). Third, in adipose tissue, eLOX3 generated PPARγ agonists in the absence of identifiable upstream
lipoxygenases (29). However, regardless of the origin and fate of the lipid intermediaries going through
the Aloxe3 pathway, the net benefit of Aloxe3 expression involves both PPARγ-dependent and -independent
pathways. The species, origin, and precise bioactivity of the lipid intermediaries that underlie these therapeutic effects now arise as a rich topic for further interrogation.
The current study examines therapeutic effects of hepatic Aloxe3 induction. From a clinical therapeutic
perspective, virus-based genetic therapy for many monogenic diseases has already reached clinical care
(52). However, this therapeutic approach is not yet fully optimized for polygenic diseases, such as obesity,
insulin resistance, and NAFLD (53). Although our physiological, morphometric, and liver histological
data did not reveal problematic effects of Aloxe3 gene overexpression after 12 weeks (Figure 4, Figure 5,
and Supplemental Figure 4), a genetic overexpression approach at present is likely to be a more distant
clinical therapy when compared with precision small-molecule therapeutics. In addition, although the full
extent of Aloxe3 regulation has yet to be elucidated as a means to leverage Aloxe3-enhancing pathways, we
demonstrated here that Aloxe3 is potently upregulated by generalized stimuli such as fasting, trehalose feeding, serum withdrawal, and flavone-class GLUT inhibition. In contrast, canonical fasting intermediates
AMPK, PGC1α, FGF21, and PPARα were dispensable for trehalose-induced Aloxe3 expression. Accordingly, SIRT1 overexpression was insufficient to upregulate Aloxe3 in vivo. It is therefore intriguing that we
were able to achieve enhanced in vitro Aloxe3 upregulation comparable with viral Aloxe3 overexpression by
treatment with the trehalase-resistant trehalose analogue lactotrehalose (21–23, 54, 55). Our characterization of this glucose-galactose trehalose analogue, and the finding that lactotrehalose exhibits enhanced
fasting-mimetic potency, is a critical advance for at least 2 reasons. First, abundant trehalase expression in
human gut, liver, brain, kidney, and reproductive tissues raises the possibility that trehalose-based therapies
may be limited by trehalase-mediated trehalose degradation. By corollary, trehalase-resistant compounds
such as lactotrehalose are postulated to confer enhanced efficacy. Secondly, it is well understood that
GLUT8 and GLUT2 (the 2 most highly expressed hepatic glucose transporters; ref. 7) are competitively
inhibited by galactose (56–58). In light of the fact that galactose is one of the saccharide moieties that comprises lactotrehalose, the data suggest that altering the saccharide moieties in trehalose modulates potency
(and perhaps also selectivity) based on each GLUT’s substrate predilection.
Taken together, although greater detail regarding intermediary regulation of Aloxe3 is warranted, augmenting Aloxe3 expression and other components of the hepatic fasting response is now feasible through
fasting itself, glucose withdrawal, or trehalose/analogue-class GLUT inhibition. The palatability, and
heavy first-pass enterohepatic kinetics (which minimizes peripheral tissue GLUT side effects) indeed make
trehalose and its analogues especially attractive candidate nutraceuticals to elicit this response. Future
directions should interrogate the fasting response–inducing potential, kinetics, and efficacy of trehalose
and its analogs in mitigating metabolic disease (21, 25, 59). In addition, it will be critical to understand
the extent to which Aloxe3 regulation in other tissues is necessary or sufficient to augment tissue-specific
adaptive fasting responses. Finally, understanding the full cadre of epoxyalcohols and other lipid products
of eLOX3 enzymatic activity, and their specific roles in the mitigating metabolic disease, are of special
pharmaceutical and clinical interest (15, 60–63).
In summary, we identified the lipoxygenase Aloxe3 as a potentially novel effector of the hepatic fasting response that is sufficient to augment basal caloric expenditure, and ameliorate insulin resistance,
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weight gain, and hepatosteatosis. (the meaning I hope to convey is that Aloxe3 does all of the above).
The rapidly rising prevalence of each of these major public health problems throughout the Western
and developing worlds mandates novel therapeutic pathway generation and leveraging thereof. We
assert that further interrogation into how hepatic glucose transport mediates the networked adaptive
hepatic fasting response will advance the field toward new and effective human therapy against metabolic disease.

Methods
Mouse models and treatment. All mice were caged in specific pathogen-free barrier housing with 12-hour
light-dark cycles and free access to water and rodent chow. For transgenic studies, WT C57B/6J mice and
Leprdb/db mice were obtained directly from the Jackson Laboratory. Upon arrival, mice were randomized to
experimental assignments and equilibrated for a minimum of 7 days in the specific pathogen-free vivarium
with automated 12-hour light-dark cycles and free access to water and rodent chow. Prior to initiating
metabolic measurements. ATG16L1HM mice were a provided by Herbert “Skip” W. Virgin’s laboratory
(Washington University School of Medicine) (64). PPARγ-LKO mice were obtained directly from the
Jackson Laboratory to the laboratory of David Rudnick (Washington University School of Medicine)
and, after propagation, were provided for experimentation.
Adeno-associated viruses overexpressing either GFP or Aloxe3 under control of the thyroid binding globulin (TBG) promoter were obtained as ready-to-use viral stocks from Vector Biolabs. Viral
particles (1 × 1011 per animal) were injected via tail vein in 6-week-old mice 10 days prior to dietary
initiation or 38 days prior to sacrifice in the genetic obesity model (e.g., 10 days rest period + 28 day
dietary stimulus) Aloxe3 expression was quantified in pilot experiments by qPCR analysis of hepatic
tissue, skeletal muscle tissue, and brown and epididymal WAT 10 days after injection and confirmed
selective hepatic Aloxe3 overexpression (not shown).
Antisense oligonucleotides (ASOs) were obtained from IONIS Pharmaceuticals as ready-to-inject
oligomers, and they were used precisely as described previously (65). GW9662 was obtained from Cayman
Chemicals (catalog 70785). WD is from Harlan Teklad (catalog TD88137); HTF-C diet is from Research
Diets (catalog 09100301).
Lactotrehalose synthesis and purification. Synthesis and purification of lactotrehalose was carried out precisely as described (66). We confirmed 98%–99% purity by 1H-NMR (not shown).
Lipoxygenase activity assay. LOX activity was quantified using a lipoxygenase activity assay kit (Biovision, catalog 978-100) per manufacturer instructions.
Serum analyses. Fasting blood glucose was measured via glucometer using tail vein blood. For all other
serum analyses, submandibular blood collection was performed immediately prior to sacrifice, and serum
was separated. Insulin ELISA (MilliporeSigma, catalog EZRMI-13K), TG (Thermo Fisher Scientific, catalog TR22421), cholesterol (Thermo Fisher Scientific, catalog TR13421), and free FA (FFA) (Wako Diagnostics, catalog 999-34691, 995-34791, 991-34891, and 993-35191) quantification was performed using
commercially available reagents according to manufacturer’s directions. Albumin levels were quantified
using an AMS LIASYS Chemistry Analyzer.
Hepatic lipids. Lipids were extracted from ~100 mg hepatic tissue homogenized in 2:1 chloroform/
methanol. Extract (0.25%–0.5% of each) was evaporated overnight prior to biochemical quantification of
TGs, LDL-C, cholesterol, and FFA using reagents described above, according to manufacturer’s directions.
Oil Red O staining. Methanol-fixed frozen sections from WT and transgenic mice were stained according to described protocols (7, 9, 12).
Body composition analysis and indirect calorimetry. Body composition analysis was carried out in unanesthetized mice as described (7, 8, 67) using an EchoMRI 3-1 device (Echo Medical Systems) via the Washington University Diabetic Mouse Models Phenotyping Core Facility.
The first 4 hours in the cage were unmeasured in order to allow for acclimation time. Thereafter, the
oxygen and CO2 consumption and production were quantified for a minimum of 1 light cycle (0601–
1800 hours) and for 1 dark cycle (1801–0600 hours). Volume O2 (VO2), VCO2, heat, movement, and
respiratory exchange ratio (RER) were automatically calculated using TSE Phenomaster software.
In vitro metabolism (Seahorse XF96) assays. Seahorse assays were performed using a Seahorse XF96 analyzer Mito Stress Test Kit (Agilent Technologies) according to manufacturer specifications. Hepatocyte
cultures were seeded at 20,000 cells per well prior to assay.
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Immunoblotting. Immunoblotting was performed as described (67). Anti-GAPDH (catalog 5174) was
obtained from Cell Signaling Technologies. LC3B antiserum was obtained from Novus Biologicals (catalog
NB-100-2200).
Indirect calorimetry. Oxygen consumption, CO2 production, RER, and heat production were measured
using the Phenomaster system (TSE) via the Washington University Diabetic Mouse Models Phenotyping
Core Facility as described (8, 67). Metabolic parameters were documented every 13 minutes.
Cell cultures and treatment. Primary murine hepatocytes obtained from WT mice were isolated as
described (7, 9–11) and cultured and maintained in regular DMEM growth media (MilliporeSigma, catalog D5796) containing 10% FBS. For in vitro starvation experiments, starved media containing 1 g/l
glucose and 0.5% FBS was used. Cultures were lysed in Trizol and subjected to downstream analysis. In
vitro genetic knockdown was achieved via siRNA transfection using Lipofectamine 3000 from Invitrogen
(catalog L3000015). Trehalose was obtained from MilliporeSigma and was >97% purity by HPLC. Trehalose water (3%, w/v) fed ad libitum was used in all in vivo experiments. Huh7 and HepG2 cell lines
were obtained directly from the American Type Culture Collection (ATCC). Human primary hepatocyte
cDNAs were obtained directly from Sciencell (catalog 5204).
qPCR. qPCR was performed as previously reported (7, 12) with some modifications. Snap-frozen livers
or cultured hepatocytes were homogenized in Trizol reagent (Invitrogen, catalog 15596026). RNA isolated
according to the manufacturer’s protocol was reverse-transcribed using the Qiagen Quantitect reverse transcriptase kit (Qiagen, catalog 205310). cDNA was subjected to qPCR using the SYBR Green master mix
reagent (Applied Biosystems, catalog 4309155). Expression data are depicted as a mean ratio of target gene
expression relative to 36B4 (housekeeping gene) expression in each sample, ± SEM. Primer sequences for
qPCR are shown in Supplemental Table 1.
RNA-seq. RNA-seq was performed by the Washington University Genome Technology Access Center
(GTAC). Primary data, processed data, and metadata for these experiments were deposited in the Gene
Expression Omnibus (www.ncbi.nlm.nih.gov/geo), with accession number GSE116516.
Library preparation was performed with 10 μg of total RNA with a Bioanalyzer RIN score greater than
8.0. Ribosomal RNA was removed by poly-A selection using Oligo-dT beads (mRNA Direct kit, Invitrogen). mRNA was then fragmented in buffer containing 40 mM tris acetate pH 8.2, 100 mM potassium acetate, and 30 mM magnesium acetate and heated to 94°C for 150 seconds. mRNA was reverse transcribed
to yield cDNA using SuperScript III RT enzyme (Invitrogen, per manufacturer’s instructions) and random
hexamers. A second strand reaction was performed to yield double-stranded cDNA (ds-cDNA). cDNA was
blunt ended, had an A base added to the 3′ ends, and then had Illumina sequencing adapters ligated to the
ends. Ligated fragments were then amplified for 12 cycles using primers incorporating unique index tags.
Fragments were sequenced on an Illumina HiSeq-3000 using single reads extending 50 bases.
RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.
Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount
version 1.4.5. Transcript counts were produced by Sailfish version 0.6.3. Sequencing performance was
assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts
detected, ribosomal fraction known junction saturation, and read distribution over known gene models
with RSeQC version 2.3.
To enhance the biological interpretation of the large set of transcripts, grouping of genes/transcripts
based on functional similarity was achieved using the R/Bioconductor packages GAGE and Pathview.
GAGE and Pathview were also used to generate pathway maps on known signaling and metabolism pathways curated by Kyoto Encyclopedia of Genes and Genomes (KEGG).
Liquid chromatography-tandem mass spectral analysis of eicosanoids. Eicosanoids (5-HETE, 12-HETE, and
12-KETE) were extracted with 300 μl of 1:1 methanol/water, containing 2 ng deuterated 12-HETE-d8
(Cayman Chemical) as the internal standard. This extract (33% of total) was injected; therefore, 0.67 ng
represents the total internal standard analyzed. The quantity of eicosanoids calculated based on the peak
are the ratio between the analyte and internal standard. Eicosanoid and internal standard analyses were
performed using a Shimadzu 20AD HPLC system, and a LeapPAL autosampler coupled to a tandem
mass spectrometer (API 4000, API-Sciex). These were operated in negative ion MRM mode. The sample
was injected on to a Thermo-Keystone betasil C-18 HPLC column (2 × 100 mm, 3 μm) with mobile
phases (A, 5 mM ammonium fluoride in water; B, 100 % acetonitrile). The data processing was conducted
with Analyst 1.6.3 (API-Sciex).
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ITT. ITT was performed precisely as reported previously (8). Briefly, mice were fasted 4 hours prior to
i.p. administration of 0.75 U/kg insulin. Glucose was monitored by glucometer (One Touch Ultra, Lifescan) over the course of 2 hours following injection.
Statistics. Data were analyzed using GraphPad Prism version 6.0 (RRID:SCR_015807). A P value
less than 0.05 was defined as statistically significant. Data shown are as mean ± SEM. Unpaired 2-tailed
homoscedastic t tests with Bonferroni post hoc correction for multiple comparisons were used for all analyses unless otherwise noted in the figure legends. Two-way ANOVA was also used for analyses with 2 independent variables.
Study approval. All animal procedures were reviewed and approved by the Washington University
School of Medicine Animal Studies Committee.
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